Screener
ArriVent BioPharma, Inc. AVBP Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock $0.0001 par value, 200,000,000 shares authorized; 45,308,941 and 42,452,251 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 4 |
| Additional paid-in capital | 772,206 | 711,847 |
| Accumulated deficit | (447,961) | (404,641) |
| Accumulated other comprehensive income (loss) | (270) | 14 |
| Total stockholders’ equity | 323,980 | 307,224 |
| Total liabilities and stockholders’ equity | $349,295 | $333,169 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s total equity?
- ArriVent BioPharma, Inc. (AVBP) reported total equity of $323.98M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total equity changed year-over-year?
- ArriVent BioPharma, Inc.'s total equity increased by 60.0% year-over-year, from $202.54M to $323.98M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total equity?
- Over 3 years (2022 to 2025), ArriVent BioPharma, Inc.'s total equity has grown at a 53.4% compound annual growth rate (CAGR), from -$85.11M to $307.22M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about ArriVent BioPharma, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude